1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87
Jorge Moreno, an obesity specialist at Yale Medicine, is already getting messages from his patients asking about the Bridge program, including some who had been denied coverage in the past
Reconstitution: Add 3.0 mL bacteriostatic water ~26.7 mg/mL total concentration Component ratio: Equal low-dose peptides + higher GHK-Cu concentration Typical daily dose: ~2.67 mg once daily Measurement: 1 unit (0.01 mL) 267 mcg total peptide Administration: Once daily (subcutaneous) Storage: Refrigerate after mixing
Patients may present with fatigue as myalgia, muscle weakness, exercise intolerance, myoglobinuria and recurrent rhabdomyolysis
They truly care